|
DEG highly-expressed in parenchyma vs. fat pad
| | | |
|
Cell Cycle: G2/M DNA Damage Checkpoint Regulation
|
0.0025
|
0.114
|
7
|
|
Nitric Oxide Signaling in the Cardiovascular System
|
0.0028
|
0.114
|
9
|
|
Actin Cytoskeleton Signaling
|
0.0001
|
0.014
|
22
|
|
p53 Signaling
|
0.0014
|
0.114
|
11
|
|
Wnt/β-catenin Signaling
|
0.0071
|
0.193
|
15
|
|
PI3K/AKT Signaling
|
0.0071
|
0.193
|
13
|
|
DEG highly-expressed in fat pad vs. parenchyma1
| | | |
|
Propanoate Metabolism
|
0.0000
|
0.000
|
12
|
|
Metabolism of Xenobiotics by Cytochrome P450
|
0.0000
|
0.001
|
11
|
|
Valine, Leucine and Isoleucine Degradation
|
0.0000
|
0.001
|
11
|
|
Butanoate Metabolism
|
0.0001
|
0.002
|
10
|
|
Glutathione Metabolism
|
0.0001
|
0.002
|
9
|
|
Pyruvate Metabolism
|
0.0001
|
0.002
|
11
|
|
Fatty Acid Metabolism
|
0.0003
|
0.004
|
12
|
|
Citrate Cycle
|
0.0003
|
0.004
|
7
|
|
Glycolysis/Gluconeogenesis
|
0.0009
|
0.009
|
11
|
|
Synthesis and Degradation of Ketone Bodies
|
0.0020
|
0.016
|
4
|
|
Fatty Acid Elongation in Mitochondria
|
0.0030
|
0.022
|
4
|
|
Oxidative Phosphorylation
|
0.0085
|
0.055
|
13
|
|
Tryptophan Metabolism
|
0.0087
|
0.055
|
9
|
|
Pentose Phosphate Pathway
|
0.0098
|
0.056
|
5
|
|
Mitochondrial Dysfunction
|
0.0000
|
0.000
|
19
|
|
LPS/IL-1 Mediated Inhibition of RXR Function
|
0.0000
|
0.000
|
20
|
|
Xenobiotic Metabolism Signaling
|
0.0000
|
0.001
|
23
|
|
Aryl Hydrocarbon Receptor Signaling
|
0.0001
|
0.001
|
17
|
|
Acute Phase Response Signaling
|
0.0003
|
0.004
|
19
|
|
LXR/RXR Activation
|
0.0004
|
0.005
|
10
|
|
Complement System
|
0.0004
|
0.005
|
7
|
|
TR/RXR Activation
|
0.0013
|
0.012
|
11
|
|
α-Adrenergic Signaling
|
0.0013
|
0.012
|
12
|
|
NRF2-mediated Oxidative Stress Response
|
0.0014
|
0.012
|
18
|
|
Cardiac β-Adrenergic Signaling
|
0.0014
|
0.012
|
13
|
|
cAMP-mediated Signaling
|
0.0055
|
0.038
|
13
|
|
IL-8 Signaling
|
0.0081
|
0.055
|
16
|
|
IGF-1 Signaling
|
0.0098
|
0.118
|
11
|
